EMERGENCE THERAPEUTICS
Emergence Therapeutics is a European biopharmaceutical company developing novel antibody-drug conjugates (ADC) to treat high-need cancers. Its lead program combines a highly specific antibody with optimized linker and payload technology to target Nectin-4 – an important target for a broad range of cancers which has been clinically validated as an ADC target by enfortumab vedotin, now approved for the treatment of urothelial cancers by the US Food and Drug Administration. Emergence is also actively exploring opportunities to develop further first- or best-in-class ADCs driven by therapeutic need.
EMERGENCE THERAPEUTICS
Social Links:
Industry:
Biotechnology Fitness Health Care Wellness
Founded:
2019-01-01
Address:
Duisburg, Nordrhein-Westfalen, Germany
Country:
Germany
Website Url:
http://www.emergencetx.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
87 M EUR
Similar Organizations
Asana Rebel
Asana Rebel is a young and growing startup committed to creating highly engaging health and fitness experiences.
Clue
Clue is a female health application that tracks period and fertility cycle.
Fitternity
India's largest online fitness platform that provides an integrated eco-system to help users start & sustain their fitness journey.
TeleClinic
TeleClinic is a communication platform that enables simple and secure communication between doctors and patients all over Germany.
Current Advisors List
Current Employees Featured
Founder
Investors List
Surveyor Capital
Surveyor Capital investment in Series A - Emergence Therapeutics
Gruenderfonds Ruhr
Gruenderfonds Ruhr investment in Series A - Emergence Therapeutics
OrbiMed
OrbiMed investment in Series A - Emergence Therapeutics
Pontifax
Pontifax investment in Series A - Emergence Therapeutics
Bpifrance
Bpifrance investment in Series A - Emergence Therapeutics
Hadean Ventures
Hadean Ventures investment in Series A - Emergence Therapeutics
NRW.BANK
NRW.BANK investment in Series A - Emergence Therapeutics
High-Tech Grunderfonds
High-Tech Grunderfonds investment in Series A - Emergence Therapeutics
Kurma Partners
Kurma Partners investment in Series A - Emergence Therapeutics
RA Capital Management
RA Capital Management investment in Series A - Emergence Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-07 | Emergence Therapeutics strengthens leadership team with the appointment of Hatem Azim as Chief Medical Officer |
Official Site Inspections
http://www.emergencetx.com
- Host name: ec2-18-188-128-145.us-east-2.compute.amazonaws.com
- IP address: 18.188.128.145
- Location: Columbus United States
- Latitude: 39.9653
- Longitude: -83.0235
- Metro Code: 535
- Timezone: America/New_York
- Postal: 43215
More informations about "Emergence Therapeutics"
Emergence Therapeutics - Crunchbase Company …
Dec 7, 2021 Contact Email [email protected] Emergence Therapeutics is a European biopharmaceutical company developing novel antibody-drug conjugates (ADC) to treat high-need cancers. Its lead program combines a …See details»
Emergence Therapeutics AG - Life-Sciences-Europe.com
Https://www.emergencetx.com Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high …See details»
Emergence Therapeutics AG - Duisburg, Germany - bionity.com
Nov 27, 2020 emergencetx.com. Contact. Profile Products News. Contact. About Emergence Therapeutics. Emergence Therapeutics is a European biopharmaceutical company developing …See details»
Emergence Therapeutics - VentureRadar
Website: https://emergencetx.com/ Develops novel antibody drug conjugate immuno-therapeutics for high-need cancers using proprietary ATAC technology, targeting Nectin ...See details»
Emergence Therapeutics - PitchBook
Emergence Therapeutics General Information Description. Developer of novel immuno-therapeutics designed to treat high-risk cancers. The company's therapeutics use ATAC …See details»
Emergence Therapeutics • life science startup | HTGF
Series A round led by Pontifax and includes new and existing investorsLead product is a next-generation Nectin-4 ADC designed to increase efficacy and minimize toxicityStrategy is to …See details»
Emergence Therapeutics - Craft
Emergence Therapeutics has 5 employees across 2 locations and $98.2 m in total funding,. See insights on Emergence Therapeutics including office locations, competitors, revenue, …See details»
HTGF Financing Emergence Therapeutics | HTGF
Dec 7, 2021 www.emergencetx.com. Consilium Strategic Communications Chris Gardner, Maya Bennison, Oscar Kennaway Email: [email protected] Tel: +44 (0)20 3709 …See details»
Emergence Therapeutics (Emergence Therapeutics AG) - Startbase
Date News; 03.10.2024 11:34: Kurma Partners raises €140 million first close of new €250 million Biofund IV Paris-based Kurma Partners, an asset manager focused on improving human …See details»
Emergence Therapeutics raises €87 million Series A financing to …
Dec 7, 2021 Jack Elands, CEO of Emergence Therapeutics, commented: “The completion of this significantly oversubscribed round enables Emergence to execute on its strategy to become a …See details»
Emergence Therapeutics | EU-Startups
Emergence Therapeutics is a European biopharmaceutical company developing novel antibody-drug conjugates (ADC) to treat high-need cancers. Its lead program combines a highly specific …See details»
Mablink Bioscience and Emergence Therapeutics Enter Into a …
Oct 21, 2021 Jack Elands, PhD Chief Executive Officer E: jelands[at]emergencetx.com M: +33 6 38 35 70 08 Emergence Therapeutics AG Schifferstrasse 210, D-47059 Duisburg, Germany …See details»
Emergence Therapeutics raises €87 million Series A ... - Hadean …
Dec 10, 2021 Series A round led by Pontifax and includes new and existing investors Lead product is a next-generation Nectin-4 ADC designed to increase efficacy and minimize toxicity …See details»
Emergence Therapeutics raises €87 million Series A financing to …
Dec 7, 2021 Emergence is also actively exploring opportunities to develop further first- or best-in-class ADCs driven by therapeutic need. Emergence is based in Duisburg, Germany with a …See details»
Emergence Therapeutics strengthens leadership team with the
Jun 7, 2022 Emergence Therapeutics strengthens leadership team with the appointment of Hatem Azim as Chief Medical Officer. Duisburg, Germany, 7 June 2022. Emergence …See details»
Emergence Therapeutics Licenses Synaffix ADC Technology …
Sep 6, 2022 www.emergencetx.com About The Synaffix ADC Platform Technology Synaffix’ proprietary ADC technology platform consists of GlycoConnect™, HydraSpace™ and …See details»
Mablink Bioscience and Emergence Therapeutics Enter Into a
Oct 21, 2021 LYON, France & DUISBURG, Germany--(BUSINESS WIRE)-- Mablink Bioscience S.A.S. a biotechnology company developing a pipeline of ADC based on its proprietary …See details»
Emergence Therapeutics Licenses Synaffix ADC Technology …
Sep 6, 2022 www.emergencetx.com About The Synaffix ADC Platform Technology Synaffix' proprietary ADC technology platform consists of GlycoConnect™, HydraSpace™ and …See details»
Emergence Therapeutics Licenses Synaffix ADC Technology …
Sep 6, 2022 Synaffix B.V. (Synaffix) and Emergence Therapeutics AG (“Emergence”) (“the Companies”) today announce that the Companies have entered into a licensing agreement of …See details»
Emergence Therapeutics raises €87 million Series A - GlobeNewswire
Dec 7, 2021 Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC. Series A round led by Pontifax and includes new and existing investorsSee details»